Hackh's Chemical Dictionary, 4th Edition, 1969, Julius Grant, ed., McGraw-Hill Book Company, New York, pp. 474-445. |
Baldessarini, R. Drugs and the treatment of psychiatric disorders. Goodman & Gilman's The Pharmacological Basis of Therapeutics 9th Edition. Hardman et al. eds. 1996 p. 399 and Ch 18: 431-459, McGraw-Hill New York. |
Crown W. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. Acta Psychiatr Scand Suppl. 2000;403:62-6. |
Epstein et al. 1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents. J Med Chem. 1981 May 1981 ; 24(5):481-90. |
Frazer A. Norepinephrine involvement in antidepressant action. J Clin Psychiatry. 2000;61 Suppl 10:25-30. Review. |
Fredman et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry. Jun. 2000;61(6):403-8. |
Meyerson et al. Allosteric interaction between the site labeled by [3H]imipramine and the serotonin transporter in human platelets. J Neurochem. Feb. 1987;48(2):560-5. |
Scates et al. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother. Nov. 2000;34(11):1302-12. |
Simon et al. TCAs or SSRls as initial therapy for depression? J. of Family Practice. Nov. 1999 48:845-6. |
Wong et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000 May 1;47(9):818-29. |